This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Barnard, L. Articles by O'Brien, G. Search for Related Content PubMed PubMed Citation Articles by Barnard, L. Articles by O'Brien, G. Social Bookmarking                         What's this?

A systematic review of the use of atypical antipsychotics in autism

Developmental Psychiatry Research Unit

A. H. Young

Stanley Foundation Research Centre, School of Neuroscience and Psychiatry, University of Newcastle, Newcastle upon Tyne; School of Neuroscience and Psychiatry, University of Newcastle, Department of Psychiatry, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK; a.h.young{at}ncl.ac.uk

J. Pearson

Developmental Psychiatry Research Unit

J. Geddes

Centre for Evidence Based Mental Health, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford

G. O'Brien

Developmental Psychiatry Research Unit, University of Northumbria, Newcastle upon Tyne, UK

Conventional antipsychotic medication is commonly prescribed to patients with autistic spectrum disorder. However, a high incidence of severe adverse reactions highlights the need to find more favourable treatments. Atypical antipsychotics may combine efficacy in ameliorating some autistic symptoms with a lower incidence of some adverse reactions. This article reviews the use of atypical antipsychotics in autistic disorder, with particular focus on behaviour, cognition and physical well-being. Thirteen studies using risperidone, three using olanzapine, one using clozapine, one using amisulpride and one using quetiapine were identified. Few firm conclusions can be drawn due to the limitations of the studies; however, there is an indication that risperidone may be effective in reducing hyperactivity, aggression and repetitive behaviours, often without inducing severe adverse reactions. Olanzapine and clozapine may also be effective; however, there is little evidence for using amisulpride or quetiapine in this population. Randomized trials are required to clarify the effectiveness of these agents.

Key Words: atypical antipsychotics • autistic disorder • learning disability • review • risperidone

Journal of Psychopharmacology, Vol. 16, No. 1, 93-101 (2002)
DOI: 10.1177/026988110201600113


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. S. Baldwin and N. Kosky Off-label prescribing in psychiatric practice Adv. Psychiatr. Treat., November 1, 2007; 13(6): 414 - 422. [Abstract] [Full Text] [PDF]

				M. Broadstock, C. Doughty, and M. Eggleston Systematic review of the effectiveness of pharmacological treatments for adolescents and adults with autism spectrum disorder Autism, July 1, 2007; 11(4): 335 - 348. [Abstract] [PDF]

				O. Dinca, M. Paul, and N. J. Spencer Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders J Psychopharmacol, September 1, 2005; 19(5): 521 - 532. [Abstract] [PDF]

				T. A. Rugino and Y. M. Janvier Aripiprazole in Children and Adolescents: Clinical Experience J Child Neurol, July 1, 2005; 20(7): 603 - 610. [Abstract] [PDF]